Ra Capital Management, L.P. 4 D Molecular Therapeutics, Inc. Transaction History
Ra Capital Management, L.P.
- $6.64 Billion
- Q2 2024
A detailed history of Ra Capital Management, L.P. transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 5,098,211 shares of FDMT stock, worth $82.4 Million. This represents 1.61% of its overall portfolio holdings.
Number of Shares
5,098,211Holding current value
$82.4 Million% of portfolio
1.61%Shares
5 transactions
Others Institutions Holding FDMT
# of Institutions
150Shares Held
56.3MCall Options Held
55.6KPut Options Held
167K-
Black Rock Inc. New York, NY4.9MShares$79.1 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY4.4MShares$71.1 Million10.13% of portfolio
-
Goldman Sachs Group Inc New York, NY4.13MShares$66.8 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.06MShares$65.6 Million2.8% of portfolio
-
Bvf Inc San Francisco, CA3.92MShares$63.4 Million2.52% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $523M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...